Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
MTA-DE Cell Biology and Signaling Research Group, Debrecen, Hungary.
Br J Pharmacol. 2018 Jan;175(2):301-319. doi: 10.1111/bph.13819. Epub 2017 Jun 18.
Glycogen phosphorylase (GP) is the key enzyme for glycogen degradation. GP inhibitors (GPi-s) are glucose lowering agents that cause the accumulation of glucose in the liver as glycogen. Glycogen metabolism has implications in beta cell function. Glycogen degradation can maintain cellular glucose levels, which feeds into catabolism to maintain insulin secretion, and elevated glycogen degradation levels contribute to glucotoxicity. The purpose of this study was to assess whether influencing glycogen metabolism in beta cells by GPi-s affects the function of these cells.
The effects of structurally different GPi-s were investigated on MIN6 insulinoma cells and in a mouse model of diabetes.
GPi treatment increased glycogen content and, consequently, the surface area of glycogen in MIN6 cells. Furthermore, GPi treatment induced insulin receptor β (InsRβ), Akt and p70S6K phosphorylation, as well as pancreatic and duodenal homeobox 1(PDX1) and insulin expression. In line with these findings, GPi-s enhanced non-stimulated and glucose-stimulated insulin secretion in MIN6 cells. The InsRβ was shown to co-localize with glycogen particles as confirmed by in silico screening, where components of InsR signalling were identified as glycogen-bound proteins. GPi-s also activated the pathway of insulin secretion, indicated by enhanced glycolysis, mitochondrial oxidation and calcium signalling. Finally, GPi-s increased the size of islets of Langerhans and improved glucose-induced insulin release in mice.
These data suggest that GPi-s also target beta cells and can be repurposed as agents to preserve beta cell function or even ameliorate beta cell dysfunction in different forms of diabetes.
This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.
糖原磷酸化酶(GP)是糖原降解的关键酶。GP 抑制剂(GPi-s)是降低血糖的药物,可导致肝脏中葡萄糖积聚为糖原。糖原代谢与β细胞功能有关。糖原降解可以维持细胞内葡萄糖水平,从而促进分解代谢以维持胰岛素分泌,而升高的糖原降解水平则导致糖毒性。本研究旨在评估通过 GPi-s 影响β细胞中的糖原代谢是否会影响这些细胞的功能。
研究了不同结构的 GPi-s 对 MIN6 胰岛素瘤细胞和糖尿病小鼠模型的影响。
GPi 处理增加了 MIN6 细胞中的糖原含量和糖原表面积。此外,GPi 处理诱导了胰岛素受体 β(InsRβ)、Akt 和 p70S6K 磷酸化以及胰腺十二指肠同源盒 1(PDX1)和胰岛素的表达。与这些发现一致,GPi-s 增强了 MIN6 细胞的非刺激和葡萄糖刺激的胰岛素分泌。InsRβ 被证明与糖原颗粒共定位,这通过计算机筛选得到证实,其中 InsR 信号通路的成分被鉴定为糖原结合蛋白。GPi-s 还激活了胰岛素分泌途径,表现为增强的糖酵解、线粒体氧化和钙信号。最后,GPi-s 增加了胰岛的大小并改善了小鼠中葡萄糖诱导的胰岛素释放。
这些数据表明,GPi-s 还靶向β细胞,并可被重新用作保护β细胞功能甚至改善不同形式糖尿病中β细胞功能障碍的药物。
本文是关于“无需重新发明轮子即可发明新疗法:药物再利用的力量”主题部分的一部分。要查看本部分中的其他文章,请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.